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Abstract
Introduction. Neuroendocrine breast tumors represent a rare subtype of breast cancer, accounting for less than 1 % of all 
neuroendocrine neoplasms. Starting from their pathology definition, and going through their prevalence, prognosis and 
treatment, our knowledge is still really uncertain.
Materials and methods. The article presents a rare clinical observation of a neuroendocrine breast tumor. A breast fibroad-
enoma was diagnosed at the initial diagnosis stage in a private clinic; after a surgical treatment and further morphologi-
cal study, it was estimated: a diagnosis of Cancer in situ of the left breast T1N0M0, stage I. Next, 3D-conformal remote 
radiation therapy was performed on the area of the left breast.
Results and discussion. After conducting positron emission tomography, multiple metastases were detected in the lymph 
nodes, bones, and liver. Additionally, micropreparations were consulted at the Federal Reference Center in St. Petersburg 
and at an independent third-party molecular biological laboratory in Germany (Munich). Given all the instrumen-
tal, molecular biological, histological and immunohistochemical studies of the patient, an individual regimen of drug 
therapy was selected.
Conclusion. After 18 months of personalized drug therapy, we observed a positive trend and a significant decrease in 
metabolic activity according to positron emission tomography.
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Нейроэндокринный рак молочной железы.  
Клиническое наблюдение. Индивидуальный подход
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Аннотация
Введение. Нейроэндокринные опухоли молочной железы представляют собой редкий подтип рака молочной 
железы, составляя менее 1 % всех нейроэндокринных новообразований. Исходя из определения патологии, рас-
пространенности, прогноза и лечения, наши знания все еще остаются неоформленными.
Материалы и методы. В статье представлено редкое клиническое наблюдение нейроэндокринной опухоли молоч-
ной железы. Фиброаденома молочной железы диагностирована на начальном этапе в частной клинике. После 
хирургического лечения и дальнейшего морфологического исследования было оценено: диагноз «Рак in situ» 
левой груди T1N0M0, I стадия. Затем была проведена 3D-конформная дистанционная лучевая терапия в об-
ласти левой груди.
Результаты и обсуждение. После проведения позитронно-эмиссионной томографии обнаружены множествен-
ные метастазы в лимфатических узлах, костях и печени. Кроме того, по микропрепаратам консультировались 
в Федеральном справочном центре в Санкт-Петербурге и в независимой сторонней молекулярно-биологиче-
ской лаборатории в Германии (Мюнхен). Учитывая все инструментальные, молекулярно-биологические, гисто-
логические и иммуногистохимические исследования пациента, была подобрана индивидуальная схема медика-
ментозной терапии.
Заключение. После 18 месяцев индивидуальной лекарственной терапии мы наблюдали положительную дина-
мику и значительное снижение метаболической активности по данным позитронно-эмиссионной томографии.
Ключевые слова: нейроэндокринные опухоли, рак груди, молочная железа, синаптофизин, хромогранин А, пер-
сонифицированная лекарственная терапия, лучевая терапия
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Introduction
Neuroendocrine neoplasms (NENs) are a group of het-
erogeneous tumors deriving from neuroendocrine cells. 
Neuroendocrine cells are scattered around the body. 
Therefore, NENs have been reported to arise in multiple 
sites, such as central nervous system, respiratory tract, lar-
ynx, gastrointestinal tract, thyroid, skin, breast, and uro-
genital system [1].
Neuroendocrine breast tumors represent a rare subtype of 
breast cancer, accounting for less than 1 % of all neuroendo-
crine neoplasms. Starting from their pathology definition, 
and going through their prevalence, prognosis and treat-
ment, our knowledge is still really uncertain [2].
The morphological diagnosis of breast NET is a problem not 
only for novice pathomorphologists, but even for experts. 
On the whole, the clinical significance and prognosis of such 
rare forms of breast cancer as NET, mucous (mucinous) car-
cinomas are still studied insufficiently. Most often, primary 
NETs are localized in the bronchopulmonary system, gas-
trointestinal tract and pancreas, originating from neuroen-
docrine cells of the corresponding organs. The NET of these 
localizations are well studied and best classified [3].
Primary neuroendocrine neoplasms of the breast (BNEN) 
are particularly rare, accounting for less than 1  % of 
NENs. Furthermore, the definition of BNEN is still quite 
confused [4].
In the 2003 World Health Organization (WHO) Pathology 
and Genetics of Tumours of the Breast and Female Genital 
Organs, BNEN were recognized as a distinct entity requir-
ing — as diagnostic criteria — the expression of NE mark-
ers (specifically chromogranin and synaptophysin) in more 
than 50 % of cells [5–7]. It was later revised and the term 
changed into carcinomas with NE features in the 2012 WHO 
Classification of Tumours of the Breast [8]. World Health 
Organization Classification of Tumours, with the 50  % 
threshold for NE marker positivity considered arbitrary and 
therefore removed. In the more recent WHO classification 
published in 2019, BNEN can only be identified only when 
the proportion of neuroendocrine cells in samples is greater 
than 90 % [9].
BNEN are overall heterogeneous in their definition, being 
characterized by a various grade of differentiation and his-
tological overlap, and at present, they do not identify a defi-
nite clinical entity, and no specific prognosis or therapy have 
been recognized yet [2].
At the present moment, the problem of diagnosing and treat-
ing NET in Russia is in the lack of statistical data on the 
morbidity and mortality caused by this pathology, the lack of 
doctors’ knowledge (oncologists, surgeons, endocrinologists, 
gastroenterologists) about the features of diagnosis, clinical 
course, principles of antitumor treatment and the lack of pos-
sibility or inaccessibility of IHC confirmation [10].
Materials and methods
Clinical observation. Patient G., 33 years old, went to a pri-
vate clinic (March 2018) to an oncologist with complaints 
on a lump in the left mammary gland. In the result of clini-
cal examination, a rounded, smooth, easily displaced mass 
of up to 1.1 cm was revealed in the left mammary gland, at 
9 o’clock, on the edge of the nipple halo. According to the 
ultrasound examination, a round formation with a diam-
eter of about 11–12 mm was revealed. A puncture of the 
neoplasm was performed and a cytological conclusion was 
“breast fibroadenoma”. After the diagnosis of fibroadenoma 
of the left breast was established on an outpatient basis in a 
private clinic, a sectoral resection of the left breast was per-
formed.
Macroscopic picture of the tumor: a roundish formation 
of gray-white color, up to 12 mm in size, a dense area of 
yellow-pink color without clear contours up to 3 mm was re-
vealed in the section in the center of the tumor. Cytological 
examination of smears prints from a tumor section showed: 
fibroadenoma with malignancy, possibly lobular carcino-
ma in situ. Pathomorphological research showed: prolif-
erating mastopathy, fibrosing adenosis; infiltrating ductal 
breast cancer of medium malignancy. IHC study ER++, 
TS = 6 (4 + 2), PR–, HER2–, Ki67 — 30 %. Conclusion: non-
infiltrating ductal breast cancer in situ.
Postoperative diagnosis: Cancer in situ of the left breast 
T1N0M0, stage I. Further treatment was carried out in the 
Republican Clinical Oncology Center (Ufa). Considering 
the performed surgery, pathomorphological and IHC data, 
3D conformal remote radiation therapy (RRT) was car-
ried out, postoperative course, 5 days a week, on the Elekta 
Synergy apparatus on the left breast area, single PDD  — 
2,5 Gy, accumulated PDD — 45 Gy, 3 fields, bremsstrahlung 
energy of 6 MeV.
Additionally, micropreparations were consulted at the Federal 
Reference Center of St. Petersburg. Pathomorphological 
study showed that the tumor consists of small and me-
dium cells, some of which are fusiform, with a pronounced 
crash phenomenon and pronounced mitotic activity. An 
IHC study showed a positive reaction in the tumor to syn-
aptophysin and CgA; a granular reaction CKAE1/AE3 and 
a negative reaction in the tumor to CD56, p63, CK14, CD45 
was noted. Positive reaction to estrogen receptors in 20 % of 
cells (5 points), negative reaction to progesterone receptors, 
HER2–, Ki67 — 70 %. Conclusion: “Neuroendocrine breast 
cancer, grade 3, Ki67 — 70 %, small cell variant”.
Taking into account that surgical removal of the tumor and 
radiation therapy were performed, it was decided to further 
monitor the patient. It should be noted that the patient com-
plained of lumbar pain, sore throat when swallowing, and a 
number of other less significant complaints, therefore it was 
decided to perform positron emission tomography (PET). 
The study was carried out 4 months after the surgery. The 
PET conclusion: postoperative scar without foci of radio-
pharmaceuticals hyperfixation. Metabolically active metas-
tases in the cervical (SUV max 6.3), supraclavicular (SUV 
max 9.7) and subclavian (SUV max 5.1) lymph nodes, bones 
(signs of osteolytic changes with pathological hyperfixation 
of the radiopharmaceuticals in the wing of the left iliac 
bone (SUV max 4.4), L3 body (SUV max 8.4), Th7 (SUV 
max 5.4)), liver (fig. 1A).
The results of skeletal scintigraphy are metastases in the Th7, 
L3 vertebrae, 2 rib on the front right, in the left ilium.
Micropreparations were additionally consulted and a new 
IHC study was conducted in an independent third-party 
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molecular biological laboratory in Germany (Munich). The 
conclusion was received: the tumor tissue had vivid expres-
sion of estrogen receptors. In view of this, a combined hor-
mone therapy was recommended. The essence of this treat-
ment concept is to block estradiol receptors through the use 
of an aromatase inhibitor and the administration of estriol. 
The tumor cell division rate according to the study was 30 %, 
which dictated the need for cytostatic chemotherapy. The 
medication of choice in this case could be anthracyclines 
and/or gemcitabine and/or taxanes.
These preparations contain fibrosed stroma with mature 
cell ductal tissue at the edges. Intraductal proliferation of 
tumor cells with centered comedic necrosis is identified. In 
a number of zones, areas of strongly compressed cells are 
observed with suspicion for an atypical infiltrative glandu-
lar complex. Polarization — optically: dystrophic micro-
calcifications. Conclusion: “high degree ductal carcinoma 
in situ, with comedic necrosis and areas of invasive breast 
cancer NST G3 (non-specific type) with neuroendocrine 
differentiation”.
After all examinations and revisions of micropreparations, 
the Cancer in situ of the left breast [Tis (DCIS) N3M1] was 
diagnosed with metastases in the cervical, supraclavicular, 
subclavian lymph nodes, bones, liver stage 4.
Taking into consideration all the instrumental, molecular-
biological, histological and IHC studies of the patient, an 
individual therapy regimen was selected. The combination 
of exemestane 25 mg per day with everolimus 10 mg/day 
(+ zoladex under the control of the level of FSH and estra-
diol). The toxicity of the combination with everolimus is 
usually higher in comparison to the standard chemotherapy 
regimen, but the patient experienced stopping of undesir-
able effects when the dose of everolimus was reduced.
The data of PET-CT of the whole body, 2 months after 
the beginning of personalized treatment, showed a posi-
tive trend. Metabolically subactive bone metastases were 
revealed: with pathological hyperfixation of radiopharma-
ceuticals in the wing of the left iliac bone (SUVmax 2.7), L3 
body (SUVmax 2.9) (fig. 1B).
Results and discussion
After 18 months of therapy, PET-CT showed no foci of ra-
diopharmaceuticals hyperfixation; bone metastases with 
background activity, mainly with sclerosis in the wing of 
the left iliac bone, L3 body, TH7-no dynamics. Compared to 
the previous PET/CT — no negative dynamics. The patient 
continues her treatment. The pain stopped, the patient leads 
an active lifestyle.
Thus, the correct morphological diagnosis of breast NET 
can significantly expand the search for both personalized 
approaches and new therapeutic targets for the breast cancer 
treatment of [11].
Figure 1. Positron emission tomogram of patient G.: A — after surgical and radiation treatment of breast 
cancer; B — 2 months after the start of personified drug therapy
Figure 2. Microphoto. Diffuse expression of receptors to synaptophysin in a neuroendocrine breast tumor, ×200, 400
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Albeit BNEN were firstly described more than 40 years ago, 
and have been categorized more and more precisely thereaf-
ter, its rarity, together with still persisting diagnostic uncer-
tainties, hampers drawing a precise clinical and prognostic 
picture. Furthermore, the lack of randomized controlled tri-
als performed to compare different treatment strategies and 
their outcomes makes small case series the best available 
evidence on this issue, at present [12, 13].
Conclusion
In conclusion, it is likely that the cases diagnosed as pri-
mary BNEN are only minimally representative of their real 
prevalence. Only a systematic evaluation of neuroendocrine 
markers on all analyzed cases of breast cancer could give a 
reliable evaluation of the frequency of these tumors. Cancer 
registries centralizing uniform data collection, together with 
large multicentric studies, could sharpen our knowledge in 
the next future [3].
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